Observational studyJapanese journal of ophthalmology2026
Clinical features and prognosis of immune checkpoint inhibitor-associated ocular inflammation in Japanese patients: a case series.
Observational study in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.International journal of clinical oncology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the clinical features of ocular inflammation caused by immune checkpoint inhibitors (ICIs) as immune-related adverse events (irAEs) in Japanese patients. STUDY
designRetrospective observational case series.
methodsWe reviewed patients with ICI-associated ocular inflammation diagnosed at our institution in 2014-2024. Patient data-background characteristics, primary tumor, causative ICIs, time to onset, laterality, type of inflammation, irAE grade, treatment, visual outcomes, and complications-were analyzed. Stratified analyses were also performed according to the type of ICI.
resultsThe cohort included 7 males and 9 females (mean age, 62.1 ± 14.3 years). The most common primary tumor was malignant melanoma (8 patients). The causative ICIs were pembrolizumab, nivolumab, and nivolumab plus ipilimumab (5, 6, and 5 patients, respectively). The median time of onset was 64 days (12-952) post-administration, with significantly earlier onset in patients receiving nivolumab plus ipilimumab. Ocular inflammation was bilateral in 13 patients. Panuveitis (10 patients) was the most common inflammation type, and 6 patients exhibited Vogt-Koyanagi-Harada (VKH) disease-like uveitis. Grade 3 irAEs were the most frequent (11 patients). ICIs were discontinued in 15 patients and 9 required systemic corticosteroids. At the final follow-up, visual acuity had generally improved; however, 4 patients had a best corrected visual acuity of 20/40 or worse due to complications.
conclusionIn Japanese patients reviewed at our institution, ICI-associated ocular inflammation often presented as panuveitis, with VKH disease-like uveitis being relatively common. Visual impairment persisted in one-fourth of the patients, emphasizing the importance of careful management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.